Clinical Trials Browser

Prostatic Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms

Triple Negative Breast Neoplasms

Muscle Invasive Bladder Urothelial Carcinoma

Carcinoma, Non-Small-Cell Lung, Lung Diseases

Breast Neoplasms, Drug-Related Side Effects and Adverse Reactions

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Triple Negative Breast Neoplasms

Carcinoma, Transitional Cell

Breast Neoplasms, Triple Negative Breast Neoplasms

Urinary Bladder Neoplasms

Lung Neoplasms, Small Cell Lung Carcinoma

Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Glioblastoma

Carcinoma, Transitional Cell

Carcinoma, Non-Small-Cell Lung

Salivary Gland Neoplasms

Breast Neoplasms

Urothelial Bladder Carcinoma

Localized Muscle Invasive Bladder Urothelial Carcinoma

Ovarian Neoplasms

Clinical Trials

Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

NeoSTAR

SIMONE

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

Drug Screening Using IMD in Bladder Cancer

ARIAN

Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response

ADAPT-TN-IV

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

ASSET

ADJUNCT

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

SASCIA

InCITe

Sacituzumab Govitecan in Recurrent Glioblastoma

Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer

TianjinCIH

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer

A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients